H IV-1 assembly is a multistep process mediated primarily by the viral structural protein, Gag. This protein, synthesized as a polyprotein precursor, Pr55
Gag , contains four major domains: matrix (MA), capsid (CA), nucleocapsid (NC), and p6. CA and NC contain determinants for Gag multimerization, whereas p6 facilitates release of virus particles (1, 2) . In most cell types, Gag assembles on the cytoplasmic leaflet of the plasma membrane (PM). MA is required for this PM-specific targeting as well as the lipid bilayer binding of Gag. MA has bipartite entities that facilitate membrane binding of Gag: (i) the N-terminal myristoyl moiety and (ii) a highly basic region (HBR) comprising of residues 17-31 (3) (4) (5) . The N-terminal myristate is normally sequestered within the globular head domain of MA (6) , which also includes the HBR. A structural change, either through Gag multimerization or phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P 2 ] binding to MA, is required to expose the myristate and enhance membrane binding (6, 7) . This mechanism is known as the myristoyl switch (8, 9) . Structural and biochemical studies suggest that the HBR of HIV-1 MA and analogous regions of other retroviral MA are apposed to face the cytoplasmic leaflet of membranes and facilitate membrane binding by interacting with acidic lipids (4, (10) (11) (12) (13) (14) . In addition, MA, especially the HBR, has been shown to interact with RNA (15) (16) (17) (18) (19) although the role of this interaction in virus assembly is less well understood. The HBR is also implicated in other steps of virus replication such as the postentry process (for review, see ref. 20) .
Many cellular proteins that interact peripherally with the cytoplasmic leaflet of membranes have basic amino acid-rich domains (21) . The subcellular localization of these proteins generally depends on the specific binding of their basic domains with acidic lipids of target membranes. For example, the pleckstrin homology domain of phospholipase C δ1(PH PLCδ1 ) has basic residues located on the surface of a binding pocket for PI(4,5)P 2 , a PM-specific acidic lipid. These basic residues specifically interact with the phosphates on the inositol headgroup of PI(4,5)P 2 (22) . This interaction allows PH PLCδ1 to localize to the PM. Similarly, basic residues of other phosphoinositide-binding domains play crucial roles in specific interactions with target membranes.
Previously, we showed that depleting cellular PI(4,5)P 2 reduces virus release of HIV-1 significantly and relocalizes Gag from the PM to cytosol or intracellular compartments (23, 24) . Not only HIV-1, but other retroviruses such as HIV-2, murine leukemia virus, and Mason-Pfizer monkey virus also require PI(4,5)P 2 or other phosphoinositides for efficient virus release (25) (26) (27) (28) . Several studies using various in vitro techniques, including NMR, protein foot printing, liposome binding, and monolayer membrane binding, suggest that MA interacts specifically with PI(4,5)P 2 (7, 24, 29, 30) . A recent lipid analysis study demonstrated that PI(4,5)P 2 is enriched in the HIV envelope in an MA-dependent manner, confirming the MA-PI(4,5)P 2 interaction in vivo (26) . These studies suggest that MA basic residues, in particular those in the HBR, promote PI(4,5)P 2 interaction and membrane binding, as observed for basic residues in other phosphoinositide-binding domains. However, the contribution of each basic residue in the HBR to the interaction between full-length Gag and PI(4,5)P 2 -containing membrane remains to be examined.
Previous reports showed that mutating lysines 29 and 31 to threonines (29KT/31KT) within the HBR relocalizes Gag from the PM to intracellular compartments, as observed for wild-type (WT) Gag in PI(4,5)P 2 -depleted cells (31) . Consistent with the altered localization, the in vitro liposome binding assay showed that 29KT/31KT Gag binds PI(4,5)P 2 less efficiently compared to WT Gag (24) . However, the Gag-PI(4,5)P 2 interaction was not completely abolished, suggesting a role for other basic amino acids in this interaction.
In this study, toward better understanding of the Gag-PI(4,5)P 2 interaction, we sought to identify all of the basic residues in the HBR important for this interaction. We confirmed that the HBR as a whole is indeed essential for PI(4,5)P 2 interaction and efficient This article is a PNAS Direct Submission.
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This article contains supporting information online at www.pnas.org/cgi/content/full/ 0908661107/DCSupplemental. membrane binding of Gag. Surprisingly, analysis of a panel of Gag mutants revealed that a part of the HBR actually suppresses membrane binding in the absence of PI(4,5)P 2 . This suppression is likely due to inhibition of the myristate-dependent hydrophobic interaction. Furthermore, RNA bound to the HBR also inhibits Gag-membrane binding through inhibition of acidic lipid binding and to a lesser extent via suppression of myristate exposure. Altogether, these results showed that the HBR regulates membrane binding in both positive and negative manners. Data presented here suggest a unique, RNA-dependent mechanism by which HIV-1 Gag ensures specific binding to the PI(4,5)P 2 -containing membrane, i.e., the PM.
Results
The HBR of the MA Domain Is Essential for PI(4,5)P 2 -Dependent Membrane Binding of Gag. To examine whether the HBR of MA is indeed important for Gag-PI(4,5)P 2 interaction, we mutated all of the positively charged residues (6A2T) within the HBR. This mutant was then analyzed for PI(4,5)P 2 -dependent membrane binding by previously described in vitro liposome binding assay (24) . In this assay, myristoylated full-length Gag is synthesized by using rabbit reticulocyte lysates and incubated with liposomes. Liposome-bound and non-liposome-bound Gag proteins are separated by sucrose gradient membrane flotation centrifugation. As shown in Fig. 1A , compared to WT Gag, binding of 6A2T Gag to PI(4,5)P 2 -containing liposomes was significantly reduced. To examine the effect of the 6A2T change on the localization of Gag in cells, we introduced the same mutations in a Gag derivative tagged with Venus, a variant of yellow fluorescent protein (GagVenus) (24, 32) . Consistent with the weak liposome binding, 6A2T GagVenus showed a hazy, cytosolic signal in most cells. Additionally, perinuclear localization of GagVenus was observed in some cells (Fig. 1B) . This phenotype is in contrast to that of WT GagVenus that localizes predominantly on the PM. The virus release was undetectable for the 6A2T mutant. Altogether, these results suggest that the HBR likely forms a binding site for PI(4,5)P 2 and that this interaction is important for efficient Gag membrane binding and virus release.
MA Basic Residues Lys25 and Lys26 in the HBR Suppress PI(4,5)P 2 -Independent Membrane Binding and Inhibit Promiscuous Localization of Gag. To pinpoint the residues essential for Gag-PI(4,5)P 2 interaction, we analyzed liposome binding of Gag mutants with single or double amino acid substitutions of the basic residues in the MA HBR by using in vitro liposome binding assay (Figs. 1, S1, and S2). Several of these mutants have been studied with respect to other proposed MA functions (19, 20, 33, 34) . Overall, the mutants could be categorized into three different phenotypes: (i) reduced PI(4,5)P 2 binding (17KT, 17KT/29KT, and 29KT/31KT), (ii) increased PI(4,5)P 2 -independent binding (25KT/26KT), and (iii) no change compared to WT (all of the other mutants). Altogether, these experiments suggest that MA basic residues 17, 29, and 31 promote MA-PI(4,5)P 2 interaction.
Among the Gag mutants examined, the 25KT/26KT mutant, where lysines 25 and 26 were changed to threonines, showed no significant change in binding to PI(4,5)P 2 -containing liposomes. Unexpectedly, however, this mutant had significantly elevated binding to control liposomes that lack PI(4,5)P 2 (Fig. 1A) . These results suggest that, in addition to facilitating membrane binding through PI(4,5)P 2 interaction, some basic residues in the HBR inhibit PI(4,5)P 2 -independent membrane binding.
To characterize the 25KT/26KT mutant Gag further, we analyzed both virus release and localization by using cell-based assays as described (24) . Consistent with the lack of requirement for PI(4,5)P 2 observed in the in vitro liposome binding assay (Fig.  1A) , the virus release efficiency of 25KT/26KT was substantially augmented compared to WT (Fig. 1C) . Notably, 25KT/26KT GagVenus displayed promiscuous membrane binding in cells, localizing both at the PM and intracellular compartments (Fig.  1B) . Altogether, these results indicate that MA basic residues 25 and 26 inhibit PI(4,5)P 2 -independent membrane binding of Gag.
RNA Inhibits Liposome Binding of Gag. Previous studies showed that the residues Lys25 and Lys26 can interact with RNA (17) (18) (19) . Therefore, it is conceivable that the 25KT/26KT mutations abolish RNA binding and allow other MA basic residues to ]-labeled WT Gag and Gag mutants with indicated amino acid substitutions were synthesized by the in vitro transcription and translation system by using reticulocyte lysates and incubated with liposomes containing or not containing PI(4,5)P 2 . The reactions were subjected to membrane flotation centrifugation, and five 1-mL fractions were collected from each tube. Representative gels are shown in Upper. M, liposome-bound; NM, non-liposome-bound. The liposome binding efficiency was calculated as the amount of liposome-bound Gag as a fraction of total Gag. (Lower) The relative liposome binding efficiency was calculated in comparison with the binding efficiency of WT Gag with PI(4,5)P 2 -containing liposomes for each experiment. Data from three independent experiments are shown as means ± SD. P values were determined by using Student's t test as a comparison with WT (ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) HeLa cells expressing WT, 6A2T, and 25KT/26KT GagVenus were analyzed by using Nikon TE2000 microscope. (C) HeLa cells expressing HIV molecular clones encoding WT or 25KT/26KT Gag were metabolically labeled for 2 h. Cell-and virus-associated Gag were recovered by immunoprecipitation. Virus release efficiency was calculated as the amount of virus-associated Gag as a fraction of total Gag synthesized during the labeling period and normalized to the virus release efficiency of WT. The average virus release efficiencies for WT and 25KT/26KT are 7.22% and 17.85%, respectively. Data from five different experiments are shown as means ± SD. **, P < 0.01.
freely interact with acidic lipids, thereby enhancing promiscuous membrane binding. To examine whether RNA does interfere with Gag membrane binding, we first tested the effect of RNase treatment on the liposome binding of WT Gag. Remarkably, treating WT Gag with RNase before incubation with liposomes greatly enhanced interaction of Gag with control liposomes containing phosphatidylcholine (PC) and phosphatidylserine (PS) (PC+PS) (Fig. 2) . A similar increase was observed with PI (4,5)P 2 -containing liposomes [PC+PS+PI(4,5)P 2 ]. Notably, however, as we reported previously (24), a substantial amount of Gag was bound to PI(4,5)P 2 -containing liposomes even without RNase treatment (Fig. 2) . These results indicate that Gagmembrane binding is suppressed almost completely by RNA unless PI(4,5)P 2 is present.
To determine whether the phenotype of 25KT/26KT Gag can be explained by the loss of RNA binding, we examined the effect of RNase treatment on liposome binding of this mutant Gag. The enhancement of membrane binding by RNase treatment was smaller than that observed for WT, especially in the absence of PI(4,5)P 2 (Fig. 2) . These data suggest that the 25KT/26KT mutation and RNase treatment enhance membrane binding by overlapping mechanisms.
The 25KT/26KT Changes Increase the Hydrophobic Interaction with
Membranes. Efficient membrane binding of Gag requires both the myristoyl moiety and the HBR. It is still possible that the 25KT/ 26KT mutant enhances membrane binding by constitutively exposing the myristoyl moiety. To test this hypothesis, we analyzed the binding of 25KT/26KT Gag to liposomes containing PC alone. Because PC is a neutral lipid, binding of Gag to these liposomes would likely be mediated by hydrophobic interaction through N-terminal myristate moiety. Consistent with the previous findings that the myristate moiety is sequestered inside the globular head of MA, and that PI(4,5)P 2 binding is required for facilitating myristate exposure (2, 6, 7), WT Gag was unable to bind well to PC liposomes (Fig. 3) . However, the double mutant 25KT/26KT was able to bind efficiently to liposomes containing only PC (Fig. 3) . These results suggest that the 25KT/26KT mutant readily exposes the myristate. Therefore, it is likely that lysines 25 and 26 suppress nonspecific membrane binding by regulating hydrophobic interactions dependent on the myristate.
RNA Bound to MA but Not NC Inhibits Liposome Binding of Gag. As described above, RNase treatment enhanced membrane binding of both WT and to a lesser extent 25KT/26KT Gag (Fig. 2) . As RNA-mediated inhibition of membrane binding may represent a unique mode of regulation in virus assembly, we sought to understand the mechanism of this inhibition. Coimmunoprecipitation experiments showed that both MA HBR and NC facilitate RNA binding to Gag in reticulocyte lysates (Fig. S3) . To test whether RNA bound to NC is involved in the inhibition of membrane binding, we analyzed NC-deleted Gag (delNC) for RNase sensitivity. Liposome binding of delNC Gag was increased upon RNase treatment to a similar extent as WT Gag (Fig. 4A) . These results suggest that at least in the liposome binding assay, NC is not required for RNA-mediated inhibition of membrane binding of Gag. The results presented above are consistent with the possibility that RNA bound to MA HBR blocks the interaction of the HBR basic residues with acidic lipids and interferes with Gag membrane binding. However, it is also conceivable that RNA binding to the HBR might reduce myristate exposure, thereby suppressing membrane binding of Gag. Both of these possibilities are consistent with the observation that membrane binding of 25KT/26KT Gag that has readily exposed myristate (Fig. 3) is enhanced upon RNase treatment markedly but not as much as WT Gag (Fig. 2) . Hence, to further understand the mechanism by which RNA inhibits membrane binding, we analyzed the myristoylation-defective Gag mutant (1GA). Interestingly, although RNase treatment did increase membrane binding of 1GA Gag, the extent of increase depended on the composition of liposomes used in the assay. 1GA Gag bound PI (4,5)P 2 -containing liposomes as efficiently as WT Gag upon RNase treatment (Fig. 4B) . This observation strongly supports the model that interaction of basic residues in the HBR with acidic lipids is increased upon RNase treatment.
In contrast, RNase treatment increased binding of 1GA Gag to PC+PS liposomes only modestly compared to that of WT Gag. These results are consistent with the possibility that RNA also inhibits membrane binding partially by sequestration of myristate. Indeed, WT Gag did show a modest increase in PCliposome binding upon RNase treatment, whereas 1GA Gag showed no increase (Fig. 4C) . These data suggest that removal of RNA has an impact on the myristoyl switch as well. Altogether, these results indicate that RNA inhibits membrane binding both by preventing the electrostatic interaction between basic residues and acidic lipids and by suppressing the myristate-dependent hydrophobic interaction.
Discussion
Phosphoinositide-binding domains found in cellular proteins contain basic residues that are essential for interaction with acidic headgroups of phosphoinositides (21) . Similarly, the current study showed that some basic residues within the HBR (Lys17, Lys29, and Lys31) are important for efficient Gag membrane binding mediated by PI(4,5)P 2 ( Fig. 1 A) . However, our study also revealed that the HBR contains basic residues (Lys25 and Lys26) that suppress membrane binding of Gag (Fig.  1A) . This negative regulation of membrane binding by Lys25 and Lys26 likely occurs via myristate sequestration (Fig. 3) . Consistent with the increased PI(4,5)P 2 -independent liposome binding, 25KT/26KT Gag localizes promiscuously in cells and releases virus particles more efficiently than WT Gag ( Fig. 1 B and C), a phenotype reminiscent of Gag derivatives with MA globular head deletions (35) . This work also identified RNA as a negative regulator of Gag membrane binding. Several in vitro studies including this study (Fig. S3) showed that HIV-1 MA interacts with RNA via its HBR (17) (18) (19) . Therefore, competition between RNA and acidic lipids for binding to the HBR at least partly accounts for the RNA-mediated suppression of Gag membrane binding. Consistent with this hypothesis, in other in vitro experiments performed in the absence of RNA, binding of MA to PS has been Fig. 2 by using PC+PS liposomes. Data from three independent experiments are shown as means ± SD. **, P < 0.01. There is no statistically significant difference in membrane binding of RNase-treated Gag between WT and delNC. (B and C) Liposome binding of WT and 1GA Gag was analyzed as in Fig. 2 by using liposomes containing either PC+PS or PC+PS+PI(4,5)P 2 (B) or only PC (C). Data from three to five independent experiments are shown as means ± SD. ns, not significant; *, P < 0.05; **, P < 0.01. There is a statistically significant difference (*) in binding to PC+PS liposomes but not PI(4,5)P 2 -containing liposomes between WT and 1GA Gag treated with RNase. readily observed (36) (37) (38) , whereas in our system, Gag binding to the PC+PS liposomes was negligible without RNase treatment. Importantly, in contrast to PC+PS liposomes, a substantial amount of Gag binds to PC+PS+PI(4,5)P 2 liposomes even without RNase treatment (Figs. 2 and 4) . Consistent with these data, while this manuscript was in revision, Eric Barklis's group reported that PI(4,5)P 2 -containing liposomes out-compete oligonucleotides for binding to beads coated with purified myristylated MA domain (39) . Thus, it is likely that PI(4,5)P 2 , but not other acidic lipids such as PS, can bind the HBR in the presence of RNA. In addition, exposure of myristate may also be more dependent on PI(4,5)P 2 binding in the presence of RNA, because RNA binding to MA HBR also reduces myristatedependent hydrophobic interaction (Fig. 4) . In any case, our data suggest that RNA binding to MA represents an important regulatory mechanism in Gag membrane binding. It remains to be determined whether RNA bound to the HBR inhibits unregulated membrane binding in cells. In our in vitro system, the RNA concentration is estimated to be lower than that in the cytoplasm of HeLa cells. Nonetheless, the inhibition of membrane binding by RNA does not require NC, the major RNA binding domain (Fig. 4A) . However, in cells, it is likely that the viral genomic RNA bound to NC also binds MA because of their close proximity. This model is also consistent with a recently proposed folded-over conformation of Gag (40, 41) (not depicted in Fig. 5 ). Notably, two recent reports suggest that RNA export from the nucleus plays a key role in MA-mediated membrane binding of Gag (42, 43) . These authors observed that HIV Gag assembly defects linked to specific Gag mRNA export pathways could be rescued by increasing membrane binding ability of Gag, either by MA mutations or replacing MA with heterologous membrane binding domains (42, 43) . In light of the results presented here, it is possible that nuclear export pathways used by viral RNAs affect MA-RNA interactions that, in turn, influence Gag membrane binding. This hypothesis is also in agreement with the observed autoinhibition of Gag membrane binding by HIV-1 MA in murine cells (44, 45) .
It has been long known that retroviral MA interacts with RNA (15) (16) (17) (18) (19) (46) (47) (48) (49) (50) . Although genomic RNA encapsidation does not require MA in the case of HIV-1 (51), a variety of functions have been suggested for the retroviral MA-RNA interaction in the later half of the virus life cycle. These functions include (i) regulation of viral mRNA translation (18, 52) , (ii) encapsidation of genomic viral RNA (53), (iii) dimerization of encapsidated RNA (54, 55) , and (iv) enhancement of Gag assembly (56, 57) . Thus, it is tempting to speculate that binding of the HBR to both PI(4,5)P 2 and RNA may play a key role in coordinating the four-way interactions between the PM, viral RNA, MA, and NC during the late phase of the retrovirus life cycle. For example, once Gag reaches the PM, the viral RNA bound to MA might get displaced by the HBR-PI(4,5)P 2 interaction. This displaced RNA may then act as a scaffold for NC-dependent Gag multimerization and facilitate efficient particle assembly at the PM. Such a process might also require cellular proteins reported to play a role in Gag multimerization or RNA packaging, including ATP-binding cassette protein in the E subfamily (ABCE1) (58, 59) and Staufen-1 (60) . Clearly, further studies are necessary for addressing interrelationships between events during the late phase.
In summary, our data indicate that the HBR within MA modulates membrane binding in three different ways: positively by interaction with PI(4,5)P 2 , negatively by suppression of myristatedependent hydrophobic interaction, and negatively by interaction with RNA. RNA binding to MA HBR not only interferes with interactions between MA basic amino acids and acidic lipids, but also appears to reduce myristate exposure. Based on this and previous studies, we put forth the following model (Fig. 5) . Both RNA binding and suppression of myristate exposure mediated by the HBR prevent Gag from premature or nonspecific membrane binding. Once Gag reaches PI(4,5)P 2 -containing membranes such as the PM, PI(4,5)P 2 binds the HBR, which then triggers myristate exposure and stabilizes binding to the lipid bilayer. However, if myristate sequestration is blocked (e.g., by the 25KT/26KT mutations) or if RNA detaches from the HBR (e.g., by RNase treatment), Gag binds membrane in a nonspecific, PI(4,5)P 2 -independent manner (Fig. 5) . Cooperation of interactions with multiple membrane factors, which enhances the robustness and specificity of membrane binding, is prevalent in phosphoinositidebinding domains (21) . However, MA HBR is unique among these domains for integrating opposing regulatory mechanisms to ensure specificity for the target membrane that contains PI(4,5)P 2 .
Materials and Methods
Cells and Plasmids. HeLa cells were cultured and maintained in DMEM supplemented with 5% FBS. HIV-1 molecular clone pNL4-3 (61), its derivative encoding YFP-tagged Gag (pNL4-3/GagVenus) and a Gag expression vector for in vitro translation reaction, pGEMNLNR, were described (24) . pNL4-3/ 1GA, pNL4-3/25KT/26KT, pNL4-3/17KT/19RL, pNL4-3/29KT/31KT, pNL4-3/ 19RL, and pNL4-3/21RL were kind gifts from E. Freed (HIV Drug Resistance Program, National Cancer Institute, Frederick, MD) (33, 34) . Other MA changes were introduced into pNL4-3 by PCR mutagenesis. MA changes in pNL4-3 derivatives were also introduced into pGEMNLNR and pNL4-3/GagVenus by using standard molecular biology techniques. pGEMNLNR/delNC was constructed by replacing BssHII to PflMI fragment (nt 711-5297) with that of pNL4-3/delNC (a kind gift from D. Ott) (AIDS Vaccine Program, SAICFrederick, Inc., National Cancer Institute, Frederick, MD) (62).
Liposome Binding Assay. Liposome binding assay was performed as described (24) . Briefly, radiolabeled Gag is synthesized by using in vitro transcription and translation coupled reaction mix containing rabbit reticulocyte lysates (Promega). Liposomes containing corresponding lipids were added after 30 min at 30°C and incubated further for 90 min. Then, the liposome-bound and nonliposome-bound Gag were separated by equilibrium flotation centrifugation.
For RNase treatment experiments, the above protocol was modified as following. Gag synthesis was performed at 30°C for 90 min. Subsequently, 1 μL of RNase, which is a mixture of pyrimidine-specific endoribonucleases from bovine pancreas (Cat. No.: 11119915001, Roche Applied Science), was added to 25 μL of the reaction mix and incubated for 20 min at 37°C. Liposomes were then added and incubated for 15 min at 30°C before equilibrium flotation centrifugation was performed.
Virus Release Assay, Microscopy, and Statistical Analysis. Virus release assay was performed as described (23) . Microscopy and statistical analysis were performed as described (24) .
Coimmunoprecipitation of Gag and RNA. RNA binding to Gag synthesized in in vitro transcription and translation coupled reactions was analyzed as described in SI Materials and Methods.
